



Mustargen® (mechlorethamine) – Product discontinuation

- On October 4, 2018, the [FDA announced](#) the discontinuation of [Recordati Rare Diseases' Mustargen \(mechlorethamine\)](#) 10 mg injection.
 - Recordati has decided to discontinue manufacture, distribution and sale of Mustargen due to extremely low demand.
 - Sales will be allowed through December 31, 2018.
- Mustargen, administered intravenously, is indicated for the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma.
- Mustargen, administered intrapleurally, intraperitoneally, or intrapericardially, is indicated for the palliative treatment of metastatic carcinoma resulting in effusion.
- Mustargen carries a boxed warning that it is highly toxic and inhalation of dust or vapors and contact with skin or mucous membranes, especially those of the eyes, must be avoided; avoid exposure during pregnancy; extravasation of the drug into subcutaneous tissues results in a painful inflammation; and should be administered under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.